Northland Capital Markets analyst Michael Latimore downgrades Everbridge (NASDAQ:EVBG) from Outperform to Market Perform.
Immunic Announces Pricing Of $45M Public Offering Of 4.5M Shares Of Common Stock
Immunic, Inc. (the "Company") (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune